Sign Up
OverviewAPI
Anavex Life Sciences Corp. faces a class action lawsuit for alleged securities law violations related to misrepresented trial results of its primary product, blarcamesine, used in CNS disorder treatments. Bronstein, Gewirtz & Grossman, LLC, initiated the lawsuit regarding the stock price decline linked to deceptive market practices.

Ask a question